Advanced search
Publication Cover
Bioanalysis Volume 14, 2022 - Issue 7
Submit an article Journal homepage
1,110
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Bioanalysis of INCB000928 in Human Saliva: Nonspecific Binding and Inhomogeneous Concentration

Zhiyin Xun1 Drug Metabolism & Pharmacokinetics & Clinical Pharmacology, Incyte Research Institute, 1801 Augustine Cut-off, Wilmington, DE19803, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9793-4429
ORCID Icon,
Brad Yuska1 Drug Metabolism & Pharmacokinetics & Clinical Pharmacology, Incyte Research Institute, 1801 Augustine Cut-off, Wilmington, DE19803, USA
,
Phillip Wang1 Drug Metabolism & Pharmacokinetics & Clinical Pharmacology, Incyte Research Institute, 1801 Augustine Cut-off, Wilmington, DE19803, USA
&
Swamy Yeleswaram1 Drug Metabolism & Pharmacokinetics & Clinical Pharmacology, Incyte Research Institute, 1801 Augustine Cut-off, Wilmington, DE19803, USA
Pages 405-419 | Received 21 Jan 2022, Accepted 24 Feb 2022, Published online: 10 Mar 2022

References

  • De Brasi D , OrlandoF, GaetaVet al. Fibrodysplasia ossificans progressiva: a challenging diagnosis. Genes12(8), 1187 (2021).
  • Pignolo RJ , HsiaoEC, BaujatG, LapidusD, ShermanA, KaplanFS. Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: estimate from three treatment centers and a patient organization. Orphanet. J. Rare Dis.16(1), 350 (2021).
  • Kaplan FS , XuM, SeemannPet al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum. Mutat.30(3), 379–390 (2009).
  • Shi F , GaoJ, ZouJ, YingY, LinH. Targeting heterotopic ossification by inhibiting activin receptor-like kinase 2 function (review). Mol. Med. Rep.20(4), 2979–2989 (2019).
  • Yamamoto H , SakaiN, OhteSet al. Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva. Bioorg. Med. Chem. Lett.38, 127858 (2021).
  • Rooney L , JonesC. Recent advances in ALK2 inhibitors. ACS Omega6(32), 20729–20734 (2021).
  • Oh ST , GotlibJ, MohanSet al. A phase 1/2 study of INCB000928 as monotherapy or in combination with ruxolitinib in patients with anemia due to myelofibrosis (INCB 00928-104) (abstract CT216). Blood136(Suppl. 1), 3 (2020).
  • Hsiao EC , DiRocco M, CaliAet al. Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP). Br. J. Clin. Pharmacol.85(6), 1199–1207 (2018).
  • Pignolo RJ , ShoreEM, KaplanFS. FOP – diagnosis management and therapeutic horizons. Pediatr. Endocrinol. Rev.10(Suppl. 2), 437–448 (2013).
  • Kaplan FS , ChakkalakalSA, ShoreEM. Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis. Dis. Model Mech.5(6), 756–762 (2012).
  • Amara A , PenchalaSD, ElseLet al. The development and validation of a novel LC–MS/MS method for the simultaneous quantification of molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva. J. Pharm. Biomed. Anal.206, 114356 (2021).
  • Veltkamp F , PistoriusMCM, BoutsAHM, MathôtRAA. Development and validation of LC–MS-MS to determine levamisole in plasma and saliva. Ther. Drug Monit.43(2), 279–285 (2021).
  • Dziurkowska E , Jiménez-MorigosaC, López-RivadullaM, WesolowskiM. Development and validation of solid-phase extraction coupled with a liquid chromatography–tandem mass spectrometry method for quantitation of olanzapine in saliva. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci.1136, 121896 (2020).
  • Hösli R , KönigS, MühlebachSF. Development and validation of an LC–MS/MS and comparison with GC–MS method to measure phenytoin in human brain dialysate, blood, and saliva. J. Anal. Methods Chem.2018, 8274131 (2018).
  • Lood Y , AardalE, AhlnerJet al. Determination of testosterone in serum and saliva by liquid chromatography–tandem mass spectrometry: an accurate and sensitive method applied on clinical and forensic samples. J. Pharm. Biomed. Anal.195, 113823 (2021).
  • Jin Y , PanY, JinB, JinD, ZhangC. (S)-1-(5-(4-Methylpiperazin-1-yl)-2,4-dinitrophenyl)pyrrolidine-2-carboxylic acid as a derivatization reagent for ultrasensitive detection of amine enantiomers by HPLC–MS/MS and its application to the chiral metabolite analysis of (R)-1-aminoindan in saliva. J. Pharm. Biomed. Anal.194, 113815 (2021).
  • Calvo AM , SantosGM, DionísioTJet al. Quantification of piroxicam and 5′-hydroxypiroxicam in human plasma and saliva using liquid chromatography–tandem mass spectrometry following oral administration. J. Pharm. Biomed. Anal.120, 212–220 (2016).
  • Ji AJ , JiangZ, LivsonY, DavisJA, ChuJX, WengN. Challenges in urine bioanalytical assays overcoming nonspecific binding. Bioanalysis2(9), 1573–1586 (2010).
  • Nguyen JM , GilarM, KoshelBet al. Assessing the impact of NSB on oligonucleotide bioanalysis. Bioanalysis13(16), 1233–1244 (2021).
  • Zhang YF , ZhengJ, ZhengL, ZhouZR. Influence of centrifugation treatment on the lubricating properties of human whole saliva. Biosurf. Biotribol.2(3), 95–101 (2016).
  • European Medicines Agency. Guideline on bioanalytical method validation (2011). https://www.ema.europa.eu/en/bioanalytical-method-validation
  • US Food and Drug Administration. Bioanalytical method validation guidance for industry (2018). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.